FDA: "Most firms meet postmarketing study timelines" - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA: "Most firms meet postmarketing study timelines"



More than 80% of pharmaceutical and biologics companies are completing their postmarketing studies and regulatory obligations in a timely manner. The finding is a result of a new FDA study performed under contract with Booz Allen Hamilton and supported by Congress that reviewed 1531 open postmarketing studies submitted by pharmaceutical firms.

"New resources and directives from Congress have allowed us to complete this long-desired review," said Janet Woodcock, Director of the FDA’s Center for Drug Evaluation and Research in press statement. "The data indicate that makers of approved drugs and biologics are generally meeting their regulatory obligations and are on track with their studies. To date, we have not identified any previously unknown serious safety issues from the submitted final study reports."

The study included recommendations as to how companies may improve the quality of the information they submit to the FDA, the timeliness of the FDA review and the accuracy of the FDA’s databases, including:

  • Establishment of a postmarketing study development coordinator and a tracking coordinator within each new drug division.
  • Development of new manuals of policies and procedures for the development of postmarketing studies and for tracking the status of postmarketing studies.
  • Creation of a new postmarketing study database in the document archiving and records retention system that includes increased capabilities for data capture, tracking, and generating reports related to postmarketing studies.

The agency says it will continue to work with Booz Allen Hamilton to complete its review of all submitted reports in a timely manner.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here